CN103520329A - 一种治疗前列腺癌的中医药方 - Google Patents
一种治疗前列腺癌的中医药方 Download PDFInfo
- Publication number
- CN103520329A CN103520329A CN201310529009.7A CN201310529009A CN103520329A CN 103520329 A CN103520329 A CN 103520329A CN 201310529009 A CN201310529009 A CN 201310529009A CN 103520329 A CN103520329 A CN 103520329A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- prostate
- traditional chinese
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 206010060862 Prostate cancer Diseases 0.000 title abstract description 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 244000179560 Prunella vulgaris Species 0.000 claims abstract 2
- 201000001514 prostate carcinoma Diseases 0.000 claims description 29
- 241001407408 Berberis fortunei Species 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 7
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 241000893536 Epimedium Species 0.000 abstract 1
- 241001634534 Helicteres Species 0.000 abstract 1
- 244000297531 Lespedeza cuneata Species 0.000 abstract 1
- 240000003146 Lobelia chinensis Species 0.000 abstract 1
- 244000179291 Mahonia aquifolium Species 0.000 abstract 1
- 241000157511 Oldenlandia Species 0.000 abstract 1
- 241001127637 Plantago Species 0.000 abstract 1
- 244000292697 Polygonum aviculare Species 0.000 abstract 1
- 235000006386 Polygonum aviculare Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241001278833 Rosa laevigata Species 0.000 abstract 1
- 235000000661 Rosa laevigata Nutrition 0.000 abstract 1
- 241000501098 Sargentodoxa Species 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 206010017553 Furuncle Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 206010003011 Appendicitis Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 208000006750 hematuria Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010018498 Goitre Diseases 0.000 description 3
- 208000015817 Infant Nutrition disease Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 201000003872 goiter Diseases 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 208000004396 mastitis Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 239000002435 venom Substances 0.000 description 3
- 210000001048 venom Anatomy 0.000 description 3
- 231100000611 venom Toxicity 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 208000037319 Hepatitis infectious Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 241001529739 Prunella <angiosperm> Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010067868 Skin mass Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- -1 Estracyte Chemical compound 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010018866 Haematospermia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000008982 Hemospermia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000010097 fuzheng yiliu Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种治疗前列腺癌的中医药方,该药方由山芝麻、夜关门、车前草、半边莲、半枝莲、大黄、白花蛇舌草、十大功劳、金樱子、何首乌、夏枯草、淫羊藿、大血藤等常见中草药组成。该药方根据药材比例及药量调整,对于各型前列腺癌均具有一定的治疗作用。
Description
技术领域
本发明属于中医药领域,涉及一种治疗前列腺癌的中医药方。
背景技术
前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌(腺泡腺癌)、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上,因此,通常我们所说的前列腺癌就是指前列腺腺癌。2102年我国肿瘤登记地区前列腺癌发病率为9.92/10万,列男性恶性肿瘤发病率的第6位。
目前,前列腺癌的诊断方法虽然不断改进,但仍无单一最敏感、最可靠的方法。治疗前列腺癌的治疗,主要有手术治疗、激素治疗、化疗、放疗、免疫治疗等。具体选用何种方法,应根据患者年龄、全身状况、癌肿的局部范围以及转移情况而定。手术治疗对于晚期患者及年老患者不便,手术损伤恢复也困难,且仅适用于对局限性前列腺癌的治疗。内分泌与肾上腺药物治疗目前是前列腺癌特别是晚期前列腺癌的主要治疗方法。但该类药物治疗的副作用在于激素甾体类药物易于导致内分泌失调,且易发生心血管疾病。前列腺癌的化学治疗于1973年用于临床,化学治疗常在内分泌、放射治疗失败后才采用,常用的药物有阿霉素、磷酸雌二醇氮芥、环磷酰胺、5-氟尿嘧啶等。同大多数癌肿一样,前列腺癌在化疗初期很敏感,但很快产生耐药,耐药的主要原因是细胞内含有一种蛋白(P170),能将药物迅速排出细胞,是药物排出的一个泵。放射及冷冻治疗,这种方法适用于前列腺肿瘤体积较大,全身情况较差的患者,可以促进患者的免疫能力,使骨、肺等转移病灶发生退化。由于需要特殊的设备,目前尚未广泛使用。免疫治疗:当患者的前列腺癌组织用其他治疗方法减到极微量时,应用免疫疗法清除体内残余的少量癌肿组织,可能会有较好的效果。故而应用选择也比较少。
在中医经典著作中无前列腺癌的记载,但根据本病的主要临床表现及体征,中医学往往将其归入“淋证”“尿血”“积聚”等疾病范畴。近年来中医对于前列腺的认识也逐步深入,但治疗方略仍非常有限。本发明中医药方在前列腺癌治疗中,既可作为前列腺癌病人的疗方法,又可作为手术、放射、化疗的辅助治疗用药,以提高疗效,减轻毒副反应,有利于切除和术后的恢复。
技术内容
本发明的目的是提供一种治疗前列腺癌的中医药方,该组方根据药材比例及药量调整,对于各型前列腺癌均具有一定的治疗作用。
本发明治疗前列腺癌的中医药方,由下述活性成分组成:
山芝麻、夜关门、车前草、半边莲、半枝莲、大黄、白花蛇舌草、十大功劳、金樱子、何首乌、夏枯草、淫羊藿、大血藤。
本发明治疗前列腺癌的中医药方,其选用的活性药材,重量配比为:
山芝麻25份、夜关门22份、车前草7份、半边莲15份、半枝莲14份、大黄8份、白花蛇舌草19份、十大功劳14份、金樱子20份、何首乌10份、夏枯草9份、淫羊藿9份、大血藤12份。
本发明中医药方,所选用各草药的药理学基础为:
山芝麻:味苦、微甘,性寒。有小毒。解表清热,消肿解毒。
夜关门:味苦、辛,性凉。补肝肾,益肺阴,散瘀消肿。《四川中药志》:治虚弱遗尿,男子白浊,女子白带,阴虚气弱,通乳汁,疗疳疾。《湖南药物志》:清热,收敛,祛风,杀虫。
车前草:味甘、淡,性微寒。归肺经,肝经,肾经,膀胱经。补肾涩精,健脾利湿,补充痰止咳,清热解毒。主小便不利,淋浊带下,水肿胀满,暑湿泻痢,痰热咳喘。
半边莲:味甘、性平。归心经,肺经,小肠经。清热解毒,利水消肿。主治:毒蛇咬伤,痈肿疔疮,扁桃体炎,温疹,足癣,跌打损伤,湿热黄疸,阑尾炎,肠炎,肾炎,肝硬化腹水及多种癌症。
半枝莲:味辛、苦,性寒。归肺经,肝经,肾经。功能:清热,解毒,散瘀,止血,利尿消肿,定痛。《泉州本草》:清热,解毒,祛风,散血,行气,利水,通络,破瘀,止痛。内服主血淋,吐血,衄血,外用治毒蛇咬伤,痈疽,疔疮,无名肿毒。
大黄:味苦,性寒。归胃经,大肠经,肝经,脾经。攻积滞,清湿热,泻火,凉血,祛瘀,解毒。主治:实热便秘,热结胸痞,湿热泻痢,黄疸,淋病,水肿腹满,小便不利,目赤,咽喉肿痛,口舌生疮,胃热呕吐,吐血,咯血,衄血,便血,尿血,蓄血,经闭,产后瘀滞腹痛,症瘕积聚,跌打损伤,热毒痈疡,丹毒,烫伤。
白花蛇舌草:味苦、甘,性寒。无毒。入心经、肝经、脾经。功效:清热解毒,利湿。主肺热喘咳,咽喉肿痛,肠痈,疖肿疮疡,毒蛇咬伤,热淋涩痛,水肿,痢疾,肠炎,湿热黄疸,擅长治疗多种癌肿。
十大功劳:味苦,性寒。归肝、胃、大肠经。滋阴清热。主治:肺结核,感冒。根、茎:清热解毒。主治细菌性痢疾,急性肠胃炎,传染性肝炎,肺炎,肺结核,支气管炎,咽喉肿痛。外用治眼结膜炎,痈疖肿毒,烧、烫伤。
金樱子:味微苦,性寒。归肾经,膀胱经,大肠经,脾经,肺经。清热解毒,祛风利湿。用于骨髓炎,骨膜炎,黄疸型肝炎,跌打损伤,风湿筋骨痛,外用治疮疖。
何首乌:味苦、甘、涩,性微温。归肝、肾经。主治血虚贫血,头昏目眩,心悸,失眠,肝肾阴虚之腰膝酸软,须发早白,耳鸣,遗精,肠燥便秘,久疟体虚,风疹瘙痒,疮痈,瘰疬,痔疮。
夏枯草:味苦、辛,性寒。入肝、胆经。①清火明目:治目赤肿痛、头痛。②清肝火、降血压:治高血压病、高血脂、高血粘和高血糖。③散结消肿:治瘰疬、瘿瘤、乳痈肿痛。清肝、散结、利尿,治瘟病、乳痈、目痛、黄疸、淋病、高血压等症,叶可代茶。[2]治淋巴结核、甲状腺肿大、瘰疬、瘿瘤、乳痈、乳癌、目珠夜痛、羞明流泪、头目眩晕、口眼歪斜、筋骨疼痛、肺结核、急性黄疸型传染性肝炎、血崩、带下。
淫羊藿:味辛、甘,性温。归肝、肾经。补肾壮阳,祛风除湿,强筋键骨。
大血藤:性凉,味苦,无毒。《四川中药志》:″入肝。大肠二经。败毒消痈,活血通络,祛风杀虫的作用。治急、慢性阑尾炎,风湿痹痛,赤痢,血淋,月经不调,疳积,虫痛,跌扑损伤。
大血藤:味苦,性凉。无毒。入肝、大肠二经。败毒消痈,活血通络,祛风杀虫的作用。治急、慢性阑尾炎,风湿痹痛,赤痢,血淋,月经不调,疳积,虫痛,跌扑损伤。
本发明治疗前列腺癌的药物组方用于内服,可按照常规煎煮使用,也可根据临床需求根据制剂技术制成相应的丸剂、片剂、胶囊及散剂等剂型。
本发明的治疗前列腺癌的中药组方,经过数次微调,形成了较为明确的治疗疗效。
主要参考文献:[1]镡云辉,陈照彦.前列腺癌治疗进展[J].黑龙江医药,2010,23(4):531.[2]王树声,等.中医药治疗前列腺癌的探索与优势[J].中国中西医结合外科杂志,2010,16(3):263.[3]张亚强.晚期前列腺癌的中医药治疗现状与思考[J].中国中西医结合外科杂志,2008,14(4):311.[4]苏森毅,程惠华.中医药治疗前列腺癌的新进展[J].环球中医药,2012,5(2):152.[5]古炽明,吕立国,王昭辉,等.中西医结合治疗前列腺癌的临床观察[J].广东药学院学报,2007,23(1):92.[6]吕立国,陈志强,王树声,等.中西医结合扶正抑瘤法治疗前列腺癌142例临床观察[J].新中医,2008,40(1):26.[7]谭宁华,王双明,杨亚滨,等.白花蛇舌草抗肿瘤活性和初步化学研究[J].天然产物研究与开发,2002,14(5):34.[8]刘仁俊.黄柏化学成分及药理作用浅谈[J].中国中医药,2011,9(13):83.[9]谭日健.何首乌药理研究进展[J].医学文选,2000,19:145.[10]芦柏震,周俐斐,侯桂兰,等.白花蛇舌草抗肿瘤作用研究进展[J].医药导报,2009,28(3):345.[11]王天晓,李明,雷凯健,等.功劳木抗肿瘤作用研究进展[J].河南大学学报(自然科学版),2010,4:1143.[12]姚佳,彭梅,杨娟.金樱子多糖对阿奇霉素的增效减毒作用[J].山地农业生物学报,2012,31(4):338.
临床疗效
1.样本信息
临床样本来自数年来诊治的门诊患者,总病例33例。其中鳞状细胞癌2例,腺鳞癌2例,前列腺腺癌24例,导管腺癌5例。
2.疗效标准
根据前列腺癌的通用检查方法,选用血清PSA、直肠前列腺超声和盆腔MRI检查,。
完全缓解:可见肿瘤消失并持续一月以上,PSA降至正常正常水平。
部分缓解:肿瘤两个最大的相互垂直的直径乘积缩小50%以上并持续一月以上,PSA降至正常或略高于正常水平。
稳定:肿瘤两个最大的相互垂直的直径乘积缩小不足50%,增大不超过25%并持续一个月以上,PSA降至恒值水平。
恶化:肿瘤两个最大的相互垂直的直径乘积增大不超过25%,PSA水平未降低或升高。
3.治疗方法
治疗方法均是使用配比中药组方,采用煎剂口服给药方式进行。根据病情及病程长短,确定给药时间。服用5次为一个疗程。根据长期临床观察,证实连续长期服用对胃有一定刺激作用,连续服用10天,容易拉肚子,但无长期影响。治疗给药,应断续使用。
4.治疗结果
由上表可以看出,本发明中医药方,对于各型前列腺癌,具不同程度疗效作用。绝大多数的患者都能控制病情,并进而得到完全或部分缓解的效果。由于病例有限,尚未进行大规模样本筛选,从现有统计数据看,该中医药方对于前列腺癌的总有效率达到72.7%。
5.典型病例
(1)王先生,男,45岁。患者6年前发现血清PSA为7.9ng/ml,遂行前列腺粗针穿刺活检,诊断为前列腺腺癌(Gleason评分6分,3+3),6条穿刺组织中仅一条组织少于8%的部分发现前列腺肿瘤。放疗并发症造成尿毒症,经临时性血液透析和耻骨上置管后缓解,治疗进展缓慢,处于维持状态,后经人介绍,使用本发明中医药方,使用5个疗程,入院检查PSA降至0.6ng/ml;12个疗程后,PSA水平低于0.1ng/ml,处于正常水平。2年前复检,PSA水平低于0.08ng/ml,正常水平。
(2)邓先生,男,35岁。常年在外地打工,吃住都是在工地,平时饮食习惯不好。2006年,突显排尿困难,尿流缓慢、尿流中断、尿后滴沥、排尿不尽,此外,还有尿频、夜尿增多、甚至尿失禁。去医院检查确认是前列腺癌化,需要治疗。因家庭困难,挣钱不易,不愿手术治疗,于是耽搁下来,以至后来出现血尿、血精、阳痿。2006年底回家过年,来我处就医,我亲自为其调至配药,连续使用5个疗程,排尿、血尿问题解决,7个疗程后阳痿症状消失,出现正常晨勃感觉。继续巩固3个疗程,去医院复查,各项指标正常。
具体实施例
取炮制后的山芝麻25克、夜关门22克、车前草7克、半边莲15克、半枝莲14克、大黄8克、白花蛇舌草19克、十大功劳14克、金樱子20克、何首乌10克、夏枯草9克、淫羊藿9克、大血藤12克。置于砂锅中,加入3.5斤水,烧开后,文火继续煎煮40分钟,停火,冷却,滤去药渣,饮用。
每日服用一次,每付药煎煮2次,服用5次为一个疗程。
Claims (2)
1.一种治疗前列腺癌的中医药方,其特征是由如下中药组成:
山芝麻、夜关门、车前草、半边莲、半枝莲、大黄、白花蛇舌草、十大功劳、金樱子、何首乌、夏枯草、淫羊藿、大血藤。
2.如权利要求1所述的治疗前列腺癌的中医药方,其选用的活性药材重量配比为:
山芝麻25份、夜关门22份、车前草7份、半边莲15份、半枝莲14份、大黄8份、白花蛇舌草19份、十大功劳14份、金樱子20份、何首乌10份、夏枯草9份、淫羊藿9份、大血藤12份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310529009.7A CN103520329A (zh) | 2013-11-01 | 2013-11-01 | 一种治疗前列腺癌的中医药方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310529009.7A CN103520329A (zh) | 2013-11-01 | 2013-11-01 | 一种治疗前列腺癌的中医药方 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103520329A true CN103520329A (zh) | 2014-01-22 |
Family
ID=49922916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310529009.7A Pending CN103520329A (zh) | 2013-11-01 | 2013-11-01 | 一种治疗前列腺癌的中医药方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103520329A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105194550A (zh) * | 2015-10-15 | 2015-12-30 | 华东师范大学 | 一种中药复方组合物及其在抗前列腺癌中的应用 |
CN105833194A (zh) * | 2016-05-20 | 2016-08-10 | 杭州富阳高博信息技术服务有限公司 | 一种辅助治疗术后前列腺癌的药物组合物 |
-
2013
- 2013-11-01 CN CN201310529009.7A patent/CN103520329A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105194550A (zh) * | 2015-10-15 | 2015-12-30 | 华东师范大学 | 一种中药复方组合物及其在抗前列腺癌中的应用 |
CN105194550B (zh) * | 2015-10-15 | 2019-03-01 | 华东师范大学 | 一种中药复方组合物及其在抗前列腺癌中的应用 |
CN105833194A (zh) * | 2016-05-20 | 2016-08-10 | 杭州富阳高博信息技术服务有限公司 | 一种辅助治疗术后前列腺癌的药物组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101884770B (zh) | 治疗尿石症的中药制剂及其制备方法 | |
CN101879288B (zh) | 一种治疗肾积水的中药组合物 | |
CN101607011B (zh) | 一种治疗胆囊炎术后并发症的中药药物 | |
CN101569738B (zh) | 一种治疗乳腺炎、乳腺增生、乳房肿块、关节积液、跌打损伤的膏药及其制备方法与应用 | |
CN103751702B (zh) | 一种治疗乳腺癌的中药 | |
CN103656461B (zh) | 一种治疗胃癌的中药蜜丸及制备方法 | |
CN103432412B (zh) | 一种治疗乳腺增生的药物及其制备方法 | |
CN104147559A (zh) | 一种治疗妇科子宫内膜炎的中药制剂 | |
CN103272189B (zh) | 一种治疗胆结石的药物 | |
CN103520329A (zh) | 一种治疗前列腺癌的中医药方 | |
CN103585574A (zh) | 一种用于治疗多囊卵巢综合症的中药组合物 | |
CN105770691A (zh) | 一种用于治疗宫颈癌的药物制剂及其用途 | |
CN102058808A (zh) | 一种治疗风湿性关节炎的中药 | |
CN101607076B (zh) | 一种治疗尿毒症的中药药物 | |
CN105456815A (zh) | 一种抑制肿瘤的中药及制备方法 | |
CN104225569A (zh) | 一种治疗慢性肠炎的中药组合物 | |
CN103800890B (zh) | 一种治疗月经失调的药物及制备方法 | |
CN105999060A (zh) | 一种治疗妇女血瘀型癥瘕的中药组合物及其制备方法 | |
CN105832823A (zh) | 一种用于治疗原发性肝癌的药物制剂及其用途 | |
CN106266986A (zh) | 一种用于治疗子宫肌瘤的中药组合物 | |
CN105998781A (zh) | 一种治疗急性胃肠炎的药物组合物 | |
CN105688088A (zh) | 一种用于治疗更年期抑郁症综合征的药物制剂 | |
CN103550421B (zh) | 一种熏蒸治疗强直性脊柱炎的中药组合物 | |
CN106109924A (zh) | 一种治疗糖尿病的内服中药丸及其制备方法 | |
CN107753899A (zh) | 一种治疗妇女性冷淡的丸剂药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140122 |
|
WD01 | Invention patent application deemed withdrawn after publication |